.Pharmacolibrary.Drugs.N_NervousSystem.N02A_Opioids.N02AE01_Buprenorphine.Buprenorphine .Pharmacolibrary.Drugs.N_NervousSystem.N02A_Opioids.N02AE01_Buprenorphine.Buprenorphine| name: | Buprenorphine |
| ATC code: | N02AE01 | route: | sublingual |
| n-compartments | 2 |
Buprenorphine is a semi-synthetic opioid used primarily for pain management and in the treatment of opioid use disorder. It acts as a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Buprenorphine is approved for medical use in many countries and is commonly used in both pain and addiction treatment.
Pharmacokinetics in healthy adult subjects following a single sublingual tablet administration.
Gu, M, et al., & Zhu, X (2023). Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. Frontiers in pharmacology 14 1089862–None. DOI:10.3389/fphar.2023.1089862 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36744255
Ng, CM, et al., & Kraft, WK (2015). Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy 35(7) 670–680. DOI:10.1002/phar.1610 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26172282
Jones, AK, et al., & Laffont, CM (2021). Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials. Clinical pharmacokinetics 60(4) 527–540. DOI:10.1007/s40262-020-00957-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33135125